Hana Biosciences (OTCBB: HNAB) today announced that it has completed enrollment of its pivotal Phase 2 rALLy clinical trial for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE